Toludesvenlafaxine
Toludesvenlafaxine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | Toludesvenlafaxine |
| INN | toludesvenlafaxine |
| Description | Toludesvenlafaxine, also formerly known as ansofaxine and sold under the brand name Ruoxinlin, is an antidepressant which is approved for the treatment of major depressive disorder in China. It is also under development for use in other countries like the United States. It is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) and was developed by Luye Pharma Group.
|
| Classification | Small molecule |
| Drug class | antianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(C(=O)Oc2ccc(C(CN(C)C)C3(O)CCCCC3)cc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 916918-84-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4227736 |
| ChEBI ID | — |
| PubChem CID | 56955395 |
| DrugBank | — |
| UNII ID | A7CGH459FN (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use